Germline mutations in 5' to c.7914 of BRCA2 significantly increase risk of prostate cancer

Affiliations

¹ Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
² Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, China.
³ Division of Urology, Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.

Xiao-Hao Ruan et al. Asian J Androl. 2023 May-Jun.

. 2023 May-Jun;25(3):433-434.

doi: 10.4103/aja202277.

¹ Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
² Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, China.
³ Division of Urology, Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.

No abstract available

Conflict of interest statement

None

1. Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, et al. Interim results from the IMPACT study:evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol. 2019;76:831–42. - PMC - PubMed
1. Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer:implications for genetic testing in prostate cancer patients. Br J Cancer. 2011;105:1230–4. - PMC - PubMed
1. Na R, Zheng SL, Han M, Yu H, Jiang D, et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol. 2017;71:740–7. - PMC - PubMed
1. Crocetto F, Barone B, Caputo VF, Fontana M, de Cobelli O, et al. BRCA germline mutations in prostate cancer:the future is tailored. Diagnostics (Basel) 2021;11:908. - PMC - PubMed
1. Vietri MT, D’Elia G, Caliendo G, Resse M, Casamassimi A, et al. Hereditary prostate cancer:genes related, target therapy and prevention. Int J Mol Sci. 2021;22:3753. - PMC - PubMed